Valuation: Viking Therapeutics, Inc.

Market Cap 4.43B 3.87B 3.58B 3.3B 6.22B 425B 6.33B 42.64B 16.73B 208B 16.62B 16.26B 717B P/E 2026 *
-7.93x
P/E 2027 * -8.24x
Enterprise Value 3.98B 3.47B 3.21B 2.97B 5.59B 382B 5.69B 38.3B 15.03B 187B 14.93B 14.6B 644B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.21%
Yield 2026 *
-
Yield 2027 * -
1 day+0.49%
1 week-9.22%
Current month-1.96%
1 month+29.08%
3 months+7.67%
6 months+11.37%
Current year+8.71%
1 week 37.11
Extreme 37.11
42
1 month 29
Extreme 29
42.79
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
05-31Free

Chief Technology Officer

190,000 0.1636%
03-09Buy

Executive/Senior Manager

4,475 0.0039%
01-11Free

Executive/Senior Manager

180,000 0.1592%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%-9.22%+20.91%+145.47% 4.43B
+6.05%+3.69%+65.28%+89.94% 53.54B
+0.21%-6.28%+56.18%+127.90% 54.18B
+0.97%-2.65%+7.81%+433.25% 23.66B
+0.61%-3.82%-18.30%-16.21% 22.78B
+2.36%+1.06%+43.34%-6.14% 19.54B
-2.29%-1.92%+35.57%-29.14% 17.82B
-4.00%-7.88%+175.60%+343.60% 16.01B
-1.15%-4.83%+46.53%+627.30% 15.37B
-0.72%-2.63%+21.94%+186.64% 14.09B
Average +0.27%-1.47%+45.49%+190.26% 24.14B
Weighted average by Cap. +1.20%-0.48%+48.53%+163.22%

Financials

2026 *2027 *
Net sales - -
Net income -563M -492M -455M -420M -791M -54.08B -806M -5.42B -2.13B -26.48B -2.11B -2.07B -91.18B -587M -513M -475M -438M -826M -56.42B -841M -5.66B -2.22B -27.63B -2.21B -2.16B -95.13B
Net Debt -450M -394M -364M -336M -633M -43.26B -645M -4.34B -1.7B -21.18B -1.69B -1.65B -72.94B -523M -457M -423M -391M -736M -50.28B -749M -5.04B -1.98B -24.62B -1.97B -1.92B -84.77B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
59
Date Price Change Volume
26-07-14 US$38.30 +0.46% 809,329
26-07-13 US$38.12 -1.90% 2,006,678
26-07-10 US$38.86 -5.54% 2,158,829
26-07-09 US$41.14 +2.95% 1,722,342
26-07-08 US$39.96 -5.15% 3,341,213
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
38.12USD
Average target price
92.58USD
Spread / Average Target
+142.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock